Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BNIP3
REST API REST API
Homo sapiens
BNIP3 is differentially expressed in 322 experiments: 143 organism parts: bone marrow, amygdala, ... (141 more);, 223 disease states: normal, control, ... (221 more);, 114 cell types 459 cell lines 43 compound treatments and 75 other conditions.
Synonyms Nip3
Orthologs BNIP3 (Bos taurus)   Bnip3 (Mus musculus)   bnip3 (Danio rerio)   BNIP3 (Gallus gallus)   BNIP3 (2 of 2) (Danio rerio)   Bnip3 (Rattus norvegicus)   bnip3 (Xenopus laevis)   Q005W6_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term integral to mitochondrial outer membrane, defense response to virus, protein binding, apoptosis, cytoplasm, membrane, autophagic cell death, anti-apoptosis, response to hypoxia, positive regulation of apoptosis, mitochondrial envelope, identical protein binding, induction of apoptosis, nucleus, protein heterodimerization activity, chromatin remodeling, dendrite, cell death, mitochondrial membrane, nuclear envelope, protein homodimerization activity, integral to membrane, DNA fragmentation involved in apoptotic nuclear change, nucleoplasm, neuron apoptosis, GTPase binding, mitochondrion, negative regulation of mitochondrial fusion, positive regulation of protein complex disassembly, negative regulation of survival gene product expression, cellular response to mechanical stimulus, cellular response to hypoxia, negative regulation of membrane potential, induction of apoptosis by intracellular signals, interspecies interaction between organisms, cellular response to hydrogen peroxide, positive regulation of release of cytochrome c from mitochondria, brown fat cell differentiation, response to hyperoxia, regulation of mitochondrial membrane permeability, mitochondrial fragmentation involved in apoptosis, cellular response to cobalt ion, reactive oxygen species metabolic process, positive regulation of mitochondrial fission
InterPro Term BNIP3
UniProt Accession Q6NVY4, Q66K24, B4DHJ7, Q12983
Search EB-eye ENSG00000176171
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
HepG2
2
E-MTAB-37, E-GEOD-7307
453 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, ... (61 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-GEOD-1460, E-MEXP-1327, E-MEXP-2034, E-GEOD-10797
macrophage
2
E-GEOD-360, E-GEOD-8286
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3998
erythrocyte
1
E-MEXP-583
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, ... (61 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-MEXP-1327
glioblastoma
1
3
E-MTAB-62, E-GEOD-6014, E-GEOD-4290, E-MTAB-37
Classic-KS, HIV-, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
uterine fibroid
2
E-MTAB-62, E-GEOD-2724
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
217 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-2590, ... (27 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
none
3
4
E-GEOD-5824, E-GEOD-5099, E-GEOD-7400, E-GEOD-412, E-TABM-868, ... (7 experiments)
dexamethasone/8-bromo cyclic AMP/isobutylmethylxanthine (DCI)
1
E-GEOD-3306
M-CSF
1
1
E-GEOD-5099
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
vanadium pentoxide
1
E-GEOD-5339
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, E-MEXP-2340, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-MEXP-445, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-6802

Injury
studied in E-GEOD-19743, E-GEOD-5372

Irradiate
studied in E-TABM-321

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.481 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM